suplatast tosylate
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2023 (NCT05983471)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-5INHIBITOR
IL5 inhibitor
- Interleukin-4INHIBITOR
IL4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1- Mol. weight
- 328.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1180156 ↗
- ChEMBLCHEMBL115435 ↗
Also known as
- suplatast
- suplatast
- suplatast tosilate
- suplatast tosylate
- suplatast tosylate
- suplatast tosylate
- suplatast tosylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05983471 | Phase 2 | Nov 30, 2023 | Melius Pharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Melius Pharma | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1